nerve molecule red w logo 3.jpg

The largest not-for-profit scientific network of Parkinson centers in North America


Parkinson Study Group, officially designated as a 501c3 non-profit organization, has carried out cooperative therapeutic research since 1986, beginning with the NIH-sponsored DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) clinical trial.

Since then we have carried out more than 35 multi-center trials examining the symptomatic and neuroprotective effects of experimental interventions in Parkinson disease. The PSG has partnered with numerous pharmaceutical companies and the National Institutes of Health (NIH) in bringing new drugs for Parkinson disease to the market including pramipexole, entacapone, rotigotine and rasagiline.

Tax-deductible donations may be sent to:
Parkinson Study Group
C/O Donna Moszkowicz or Roseanna Battista
University of Rochester
Saunders Research Building
265 Crittenden Blvd. CU-420694
2nd Floor – 2.401G
Rochester, NY 14642-0694

Funding Resources img

Funding Resources

A collection of grants, awards and other funding available for Parkinson Disease research initiatives

Clinical Trials img

Clinical Trials

Clinical trials in progress, completed trials, PSG credentialed sites and other related resources

Study Kit img

Study Proposal Toolkit

Procedures, forms, sample projects and more, for those seeking to submit a study proposal

PSG Annual Meeting and Symposium

 See highlights from our annual Meeting and Symposium that took place in Phoenix, Arizona April 5-8, 2019.

Upcoming Events & Deadlines